XML 152 R33.htm IDEA: XBRL DOCUMENT v3.24.3

Segment Information (Tables)

9 Months Ended

Sep. 30, 2024

Segment Reporting [Abstract]

Schedule of Operations by Reportable Segment

Approximate information concerning the Company’s operations by reportable segment for the three and nine months ended September 30, 2024 and 2023 is as follows. The Company relies on intersegment cooperation and management does not represent that these segments, if operated independently, would report the results contained herein:

 Schedule of Operations by Reportable Segment

Three Months Ended September 30, 2024		Product Packaging				Commercial Lending				Direct Marketing				Biotechnology				Securities				Corporate				Total
Revenue		$	4,846,000			$	45,000			$	-			$	1,000			$	707,000			$	-			$	5,599,000
Cost of revenue			4,350,000				252,000				(2,000	)			10,000				1,993,000				-				6,603,000
Gross profit (loss)			496,000				(207,000	)			2,000				(9,000	)			(1,286,000	)			-				(1,004,000	)
Operating expense			766,000				104,000				73,000				1,169,000				901,000				654,000				3,667,000
Operating income (loss)			(270,000	)			(311,000	)			(71,000	)			(1,178,000	)			(2,187,000	)			(654,000	)			(4,671,000	)
Other income (expense)			(43,000	)			251,000				(52,000	)			(573,000	)			336,000				(949,000	)			(1,030,000	)
Net income (loss) from continuing operations before taxes			(313,000	)			(60,000	)			(123,000	)			(1,751,000	)			(1,851,000	)			(1,603,000	)			(5,701,000	)

Three Months Ended September 30,2023		Product Packaging				Commercial Lending				Direct Marketing				Biotechnology				Securities				Corporate				Total
Revenue		$	3,378,000			$	108,000			$	523,000			$	-			$	173,000			$	-			$	4,182,000
Cost of revenue			3,871,000				-				271,000				4,000				1,926,000				-				6,072,000
Gross profit (loss)			(493,000	)			108,000				252,000				(4,000	)			(1,753,000	)			-				(1,890,000	)
Operating expense			647,000				139,000				55,000				1,154,000				352,000				866,000				3,213,000
Operating income (loss)			(1,140,000	)			(31,000	)			197,000				(1,158,000	)			(2,105,000	)			(866,000	)			(5,103,000	)
Other income (expense)			(143,000	)			7,000				(1,208,000	)			6,000				(50,000	)			(189,000	)			(1,577,000	)
Net income (loss) from continuing operations before taxes			(1,283,000	)			(24,000	)			(1,011,000	)			(1,152,000	)			(2,155,000	)			(1,055,000	)			(6,680,000	)

Nine Months Ended September 30, 2024		Product Packaging				Commercial Lending				Direct Marketing				Biotechnology				Securities				Corporate				Total
Revenue		$	11,466,000			$	192,000			$	3,000			$	2,000			$	2,018,000			$	-			$	13,681,000
Cost of Revenue			10,715,000				719,000				(2,000	)			30,000				5,804,000				-				17,266,000
Gross profit (loss)			751,000				(527,000	)			5,000				(28,000	)			(3,786,000	)			-				(3,585,000	)
Operating expense			2,313,000				338,000				227,000				2,637,000				3,023,000				2,164,000				10,702,000
Operating income (loss)			(1,562,000	)			(865,000	)			(222,000	)			(2,665,000	)			(6,809,000	)			(2,164,000	)			(14,287,000	)
Other income (expense)			(118,000	)			(73,000	)			134,000				(699,000	)			52,000				(934,000	)			(1,638,000	)
Net loss from continuing operations			(1,680,000	)			(938,000	)			(88,000	)			(3,364,000	)			(6,757,000	)			(3,098,000	)			(15,925,000	)

Nine Months Ended September 30,2023		Product Packaging				Commercial Lending				Direct Marketing				Biotechnology				Securities				Corporate				Total
Revenue		$	12,883,000			$	426,000			$	1,930,000			$	3,000			$	3,678,000			$	-			$	18,920,000
Cost of revenue			10,952,000				-				820,000				67,000				6,340,000				-				18,179,000
Gross profit (loss)			1,931,000				426,000				1,110,000				(64,000	)			(2,662,000	)			-				741,000
Operating expense			1,890,000				283,000				2,683,000				3,230,000				5,946,000				2,276,000				16,308,000
Operating income (loss)			41,000				143,000				(1,573,000	)			(3,294,000	)			(8,608,000	)			(2,276,000	)			(15,567,000	)
Other income (expense)			(137,000	)			(1,943,000	)			(7,238,000	)			(2,640,000	)			16,000				(2,062,000	)			(14,004,000	)
Net loss from continuing operations			(96,000	)			(1,800,000	)			(8,811,000	)			(5,934,000	)			(8,592,000	)			(4,338,000	)			(29,571,000	)

Schedule of Disaggregation of Revenue

The following tables disaggregate our business segment revenues by major source:

Printed Products Revenue Information:      

Schedule of Disaggregation of Revenue

Three months ended September 30, 2024
Packaging Printing and Fabrication		$	4,773,000
Commercial and Security Printing			55,000
Total Printed Products		$	4,828,000

Three months ended September 30, 2023
Packaging Printing and Fabrication		$	3,293,000
Commercial and Security Printing			22,000
Total Printed Products		$	3,315,000

Nine months ended September 30, 2024
Packaging Printing and Fabrication		$	11,096,000
Commercial and Security Printing			333,000
Total Printed Products		$	11,429,000

Nine months ended September 30, 2023
Packaging Printing and Fabrication		$	12,634,000
Commercial and Security Printing			342,000
Total Printed Products		$	12,976,000

Direct Marketing

Three months ended September 30, 2024
Direct Marketing Internet Sales		$	-
Total Direct Marketing		$	-

Three months ended September 30, 2023
Direct Marketing Internet Sales		$	523,000
Total Direct Marketing		$	523,000

Nine months ended September 30, 2024
Direct Marketing Internet Sales		$	-
Total Direct Marketing		$	-

Nine months ended September 30, 2023 (as restated)
Direct Marketing Internet Sales		$	1,763,000
Total Direct Marketing		$	1,763,000

Rental Income

Three months ended September 30, 2024
Rental income		$	496,000
Total Rental Income		$	496,000

Three months ended September 30, 2023
Rental income		$	236,000
Total Rental Income		$	236,000

Nine months ended September 30, 2024
Rental income		$	1,334,000
Total Rental Income		$	1,334,000

Nine months ended September 30, 2023
Rental income		$	3,464,000
Total Rental Income		$	3,464,000

Commission Income

Three months ended September 30, 2024
Commission income		$	230,000
Total commission income		$	230,000

Three months ended September 30, 2023
Commission income		$	-
Total commission income		$	-

Nine months ended September 30, 2024
Commission income		$	737,000
Total commission income		$	737,000

Nine months ended September 30, 2023
Commission income		$	295,000
Total commission income		$	295,000

Net Investment Income

Three months ended September 30, 2024
Net Investment Income		$	45,000
Total Investment Income		$	45,000

Three months ended September 30, 2023
Net Investment Income		$	108,000
Total Rental Income		$	108,000

Nine months ended September 30, 2024
Net investment income		$	181,000
Total Management fee income		$	181,000

Nine months ended September 30, 2023
Net Investment Income		$	422,000
Total Management fee income		$	422,000

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration